2025
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry A, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel A, Finn R, Llovet J, investigators L. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet 2025, 405: 203-215. PMID: 39798578, DOI: 10.1016/s0140-6736(24)02575-3.Peer-Reviewed Original ResearchConceptsEastern Cooperative Oncology GroupNon-metastatic hepatocellular carcinomaProgression-free survivalTreatment-related adverse eventsPembrolizumab groupPhase 3 studyTransarterial chemoembolisationPlacebo groupHepatocellular carcinomaIntention-to-treatOverall survivalDouble-blindPerformance statusAdverse eventsFollow-upEastern Cooperative Oncology Group performance statusChild-Pugh class A diseaseMedian progression-free survivalSolid Tumors version 1.1Blinded independent central reviewA-fetoprotein levelAlbumin-bilirubin gradeResponse Evaluation CriteriaAs-treated populationMedian follow-up
2023
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer 2023, 13: 235-245. PMID: 38756146, PMCID: PMC11095597, DOI: 10.1159/000533991.Peer-Reviewed Original ResearchChild-Pugh class B patientsChild-Pugh B patientsClass B patientsObjective response rateProgression-free survivalChild-Pugh AB patientsOverall survivalHepatocellular carcinomaAdverse eventsLiver functionOdds ratioChild-Pugh class A patientsTreatment-related adverse eventsChild-Pugh class AHigher objective response rateShorter progression-free survivalMedian overall survivalAlbumin-bilirubin gradeImpaired liver functionClass A patientsUnresectable hepatocellular carcinomaIndividualization of treatmentChild-PughALBI grade
2022
A Retrospective Study of the Role of Perioperative Serum Albumin and the Albumin–Bilirubin Grade in Predicting Post-Liver Transplant Length of Stay
Wang R, Katz D, Lin H, Ouyang Y, Gal J, Suresh S, Labgaa I, Tabrizian P, Demaria S, Zerillo J, Smith N. A Retrospective Study of the Role of Perioperative Serum Albumin and the Albumin–Bilirubin Grade in Predicting Post-Liver Transplant Length of Stay. Seminars In Cardiothoracic And Vascular Anesthesia 2022, 27: 16-24. PMID: 36408595, DOI: 10.1177/10892532221141138.Peer-Reviewed Original ResearchConceptsPreoperative serum albuminIntensive care unit LOSIntensive care unitAlbumin-bilirubin grade 3Albumin-bilirubin gradeAlbumin-bilirubinMELD-NaTransplant recipientsRetrospective studyGrade 3Median postoperative intensive care unitHospital LOSPostoperative intensive care unitPerioperative albumin levelLiver transplant recipientsUnits of plateletsWarm ischemia timeLiver transplant outcomesHospital course dataInstitutional data warehouseLength of stayPost-liverASA scoreElixhauser Comorbidity IndexAlbumin levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply